BD reports continued strength in fourth quarter of 2014

BD has announced strong financial results for the fourth and final quarter of its 2014 business year, which ended on September 30th 2014.

During the three months, it posted a quarterly revenue total of $2.2 billion (1.39 billion pounds), up by 4.8 percent year over year, with its medical and diagnostics businesses both seeing improved results. Revenues within is biosciences division were flat.

Stronger growth was generally seen in its territories outside the US, reflecting the company's continued strength in emerging markets and the promising sales of safety-engineered products.

For the year as a whole, BD reported revenues of $8.45 billion, representing an increase of 4.9 percent over the prior-year period. It estimates that revenues for the full fiscal year 2015 will increase by between 4.5 and 5.0 percent on a foreign currency-neutral basis.

Vincent Forlenza, chairman, chief executive officer and president of BD, said: "Organic revenue growth continued to accelerate and we delivered a higher quality of earnings while maintaining our ongoing investments to support our innovation strategy."

The company is poised for further growth in the coming years following the recent acquisitions of GenCell Biosystems and CareFusion.